 |
 |
|||
|
|
|||
|
 |
Metro New Jersey Chapter Upcoming Chapter Meetings Chapter Homepage | Prior Chapter Events Licensing
Executives Society - NJ Chapter Meeting From Licensing to M&A: A Stepped-Up Challenge for L&BD Guest Speaker
Beginning in 2005, big pharma companies began acquiring Biotechs at a torrid pace, unlike anything seen in the past. Most of the new crop of acquisitions lacks marketed products -- rather, these companies possess pipelines rich in potential opportunities, generally in the early or mid-stages of human testing. For biotech companies, the “keep or partner” decision is now complicated by more than a consideration of available development dollars and the degree of market accessibility. Since IPO exits are only a remote possibility for investors, the value of the validating deal with a big pharma company has plummeted. For Pharma, the new pressure on Biotechs to re-think what were previously almost automatic partnering decisions means a reduction in the already depleted list of mid- and late-stage development compounds available for in-licensing. With deal prices climbing to previously unknown heights, even for Phase I and pre-clinical opportunities, single-product licensing discussions are now often precursors of M&A. Increasingly, L&BD professionals will be called upon to evaluate high-ticket purchases that involve consideration of multiple therapeutic areas. Our speaker will explore the implications of this stepped-up challenge for licensing and business development. Ed Saltzman is founder and President of Defined Health, a leading consultancy in business development and disease area strategy for the pharmaceutical industry. Since its founding in 1983, Defined Health has completed thousands of opportunity assessments and commercial forecasts of development stage projects for hundreds of corporate clients across the Big Pharma, Biotechnology and Specialty Pharma complex. Ed is a noted speaker on industry strategy and was one of the earliest critics of the Pharma industry blockbuster business model and its over-dependence on in-licensing late-stage blockbuster drugs to fuel growth. He was also one of the first to spot the limitation of the specialty pharma serial product acquisition model. Ed began his involvement with the pharma industry at the Ayerst Laboratories unit of American Home Products, where he had responsibility for evaluation and forecasting of compounds being considered for licensing. Prior to Ayerst, he managed the Healthcare Information Center at FIND/SVP. Ed is a member of the Licensing Executives Society and the New York Pharma Forum and is a graduate of New York University. Full bio: http://www.definedhealth.com/bios1.htm#Edward Date/Time: Location: Schedule: Dress Code: Business or Business Casual Costs and Cancellation Policies Cancellations made after 5:00pm EST, March 6 cannot be reimbursed, but substitutions are welcome! Registration and Payment Options 1. If you are a member of LES, register here with your credit card; If you are NOT a member of LES, register here with your credit card; 2. To register and pay by check, send e-mail to lindawebb@definedhealth.com Include your Name, Title, Company, Phone & E-mail Address Make check payable to: LES-NJ Local Committee Mail check and your business card to: Linda Webb Dress Code: Business Casual Linda Webb and Mary Hildebrand, Co-Chairs DIRECTIONS TO BASKING RIDGE COUNTRY CLUB FROM NORTH JERSEY: FROM CENTRAL JERSEY: FROM SOUTH JERSEY: FROM POINTS WEST: FROM NEWARK AIRPORT and
NJ TURNPIKE: NEARBY HOTELS: North Maple Inn The Inn at Somerset Hills The Olde Mill Inn The Madison Hotel The Hilton at Short Hills Somerset Hills Hotel The Grand Summit Hotel |